Poolbeg Pharma PLC (LON:POLB – Get Free Report)’s stock price dropped 0.7% during trading on Wednesday . The company traded as low as GBX 7.10 ($0.09) and last traded at GBX 7.10 ($0.09). Approximately 392,788 shares traded hands during mid-day trading, a decline of 76% from the average daily volume of 1,611,117 shares. The stock had previously closed at GBX 7.15 ($0.09).
Poolbeg Pharma Price Performance
The company has a 50-day moving average of GBX 7.68 and a 200 day moving average of GBX 10.13. The company has a market cap of £35.50 million, a PE ratio of -710.00 and a beta of 2.11.
About Poolbeg Pharma
Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.
Further Reading
- Five stocks we like better than Poolbeg Pharma
- What is Short Interest? How to Use It
- Work and Play: Investing in the Rise of Bleisure Travel
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Top Dividend Stocks to Buy Now as Bond Yields Could Lower
- What Are the U.K. Market Holidays? How to Invest and Trade
- SAP: AI Tailwinds Accelerating Enterprise Cloud Business
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
